Allianz SE Buys Shares of 2,770 Boston Scientific Co. (NYSE:BSX)

Allianz SE purchased a new position in shares of Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,770 shares of the medical equipment provider’s stock, valued at approximately $248,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. D.A. Davidson & CO. increased its position in Boston Scientific by 3.2% during the third quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider’s stock worth $917,000 after buying an additional 342 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Boston Scientific by 19.0% during the 3rd quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider’s stock worth $1,715,000 after acquiring an additional 3,261 shares in the last quarter. CreativeOne Wealth LLC increased its holdings in shares of Boston Scientific by 62.0% during the 3rd quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider’s stock valued at $375,000 after acquiring an additional 1,714 shares during the last quarter. Rockefeller Capital Management L.P. raised its stake in shares of Boston Scientific by 10.6% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 137,964 shares of the medical equipment provider’s stock valued at $11,536,000 after acquiring an additional 13,268 shares in the last quarter. Finally, Icon Wealth Advisors LLC acquired a new stake in Boston Scientific in the 3rd quarter worth approximately $100,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,302 shares of company stock worth $14,319,269. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.6 %

Shares of BSX opened at $100.95 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $102.20 and a two-hundred day moving average price of $93.30. The stock has a market cap of $149.30 billion, a price-to-earnings ratio of 80.76, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Barclays lifted their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Morgan Stanley upped their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Wells Fargo & Company lifted their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Friday, January 10th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.